September 30, 2024
Otsuka Pharmaceutical Co., Ltd.
National Cancer Center Japan
Kyushu University
Kyoto University
Nagoya Medical Center
The Institute of Medical Science, The University of Tokyo
Keio University School of Medicine
Otsuka Pharmaceutical Co., Ltd. (Tokyo); The National Cancer Center Japan (Tokyo); Kyushu University (Fukuoka); Kyoto University (Kyoto); Nagoya Medical Center (Aichi); Advanced Clinical Research Center, The Institute of Medical Science at The University of Tokyo (Tokyo); and Keio University School of Medicine (Tokyo) announce today that Otsuka Pharmaceutical has received approval to manufacture and market HemeSight®, hematological malignancies gene panel test, in Japan. Otsuka will proceed on procedures to qualify HemeSight® for health insurance reimbursement and will start marketing the test as soon as launch preparations are completed.
For further information, please refer to the following PDF file.